Catalyst Biosciences Stock Beta
| CBIODelisted Stock | USD 0.41 0.02 4.65% |
Catalyst Biosciences fundamentals help investors to digest information that contributes to Catalyst Biosciences' financial success or failures. It also enables traders to predict the movement of Catalyst Stock. The fundamental analysis module provides a way to measure Catalyst Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Catalyst Biosciences stock.
Catalyst |
Catalyst Biosciences Company Beta Analysis
Catalyst Biosciences' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Catalyst Biosciences Beta | 1.29 |
Most of Catalyst Biosciences' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Catalyst Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Catalyst Biosciences has a Beta of 1.29. This is 50.0% higher than that of the Biotechnology sector and 7.19% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Catalyst Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Catalyst Biosciences' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Catalyst Biosciences could also be used in its relative valuation, which is a method of valuing Catalyst Biosciences by comparing valuation metrics of similar companies.Catalyst Biosciences is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Catalyst Biosciences will likely underperform.
Catalyst Fundamentals
| Return On Equity | -2.69 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 51.03 M | |||
| Shares Outstanding | 37.97 M | |||
| Shares Owned By Insiders | 27.73 % | |||
| Shares Owned By Institutions | 8.75 % | |||
| Number Of Shares Shorted | 34.05 K | |||
| Price To Earning | (0.34) X | |||
| Price To Book | 0.53 X | |||
| Price To Sales | 4.82 X | |||
| Revenue | 794 K | |||
| Gross Profit | (64.91 M) | |||
| EBITDA | (52.15 M) | |||
| Net Income | (8.24 M) | |||
| Cash And Equivalents | 75.39 M | |||
| Cash Per Share | 2.39 X | |||
| Total Debt | 38 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 18.86 X | |||
| Book Value Per Share | (0.78) X | |||
| Cash Flow From Operations | (33.1 M) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (1.50) X | |||
| Price To Earnings To Growth | 0.02 X | |||
| Target Price | 16.0 | |||
| Beta | 1.29 | |||
| Market Capitalization | 19.37 M | |||
| Total Asset | 28.44 M | |||
| Retained Earnings | (410.94 M) | |||
| Working Capital | 11.38 M | |||
| Current Asset | 68.7 M | |||
| Current Liabilities | 37.76 M | |||
| Annual Yield | 7.93 % | |||
| Net Asset | 28.44 M |
About Catalyst Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Catalyst Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Catalyst Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Catalyst Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Catalyst Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Catalyst Stock
| 0.92 | KO | Coca Cola Sell-off Trend | PairCorr |
| 0.89 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.88 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.87 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.86 | TLK | Telkom Indonesia Tbk | PairCorr |
The ability to find closely correlated positions to Catalyst Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Biosciences to buy it.
The correlation of Catalyst Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |